CytoDyn Inc. (CYDY)
OQB · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Peers in Healthcare
CytoDyn Inc. has no peer companies in this window.
Recent press releases
April 2026
CytoDyn registers stock resale amid going concern warning and cash crunch
# 📜 What This Document Is 📄 This filing is a Form S-1 Registration Statement, which is a critical document that companies must file with the U.S. Securities and Exchange Commission (SEC) before they can sell securities to the public. It acts like a detailed public disclosure of the company's oper
SEC filings
All filings →Insider trades
All insider trades →CytoDyn Inc. has no reported insider trades in the last 90 days.